Holen Sie sich die Stockscreener-App
38.01
0.46%
0.17
Schlusskurs vom Vortag:
$37.84
Offen:
$38.26
24-Stunden-Volumen:
802.36K
Relative Volume:
1.33
Marktkapitalisierung:
$2.67B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-195.21M
KGV:
-11.97
EPS:
-3.1763
Netto-Cashflow:
$-176.19M
1W Leistung:
+8.09%
1M Leistung:
+8.89%
6M Leistung:
+43.40%
1J Leistung:
+58.79%
1-Tages-Spanne:
$37.05
$39.18
1-Wochen-Bereich:
$34.58
$43.25
52-Wochen-Spanne:
$20.65
$43.25
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
38.00 | 2.66B | 0 | -195.21M | -176.19M | -3.1763 |
VRTX
Vertex Pharmaceuticals Inc
|
520.57 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.10 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,006.31 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.51 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.55 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-06-11 | Eingeleitet | Guggenheim | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-25 | Eingeleitet | Wedbush | Outperform |
| 2023-08-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Eingeleitet | Bryan Garnier | Buy |
| 2022-09-13 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2022-08-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
PHVS Maintained by Wells Fargo -- Price Target Raised to $65.00 - GuruFocus
Pharvaris stock gets $60 target at H.C. Wainwright on trial data - Investing.com
Pharvaris’s deucrictibant XR cuts HAE attack rate 83% in Phase III, advancing dual oral strategy - allsci.com
Wells Fargo raises Pharvaris stock price target on strong trial data - Investing.com
RBC Raises Price Target on Pharvaris to $62 From $52, Keeps Outperform, Speculative Risk - marketscreener.com
Citizens raises Pharvaris stock price target to $79 on HAE therapy - Investing.com
Insider at Pharvaris (PHVS) lines up new stock sale - Stock Titan
Oppenheimer raises Pharvaris stock price target on trial results By Investing.com - Investing.com India
Pharvaris N.V. (PHVS) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Why is Pharvaris stock surging today? By Investing.com - Investing.com Australia
Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday - Benzinga
Why is Pharvaris stock surging today? - Investing.com
Why Is Pharvaris Stock Soaring Tuesday? - Benzinga
Premarket Movers for Sept. 8, 2026: Notable Gainers and Losers - ChartMill
Pharvaris Unveils CHAPTER-3 Phase 3 Topline Data and HAE Pipeline Milestones - TipRanks
Morning Market Movers: FCUV, BNC, BIAF, DYN See Big Swings - RTTNews
Rare swelling attacks plunge in Pharvaris (PHVS) pill trial, with key U.S. drug decisions slated for 2027. - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Pharvaris reports positive phase 3 results for HAE drug By Investing.com - Investing.com Nigeria
Pharvaris posts late-stage trial win for HAE drug (PHVS:NASDAQ) - Seeking Alpha
Pharvaris Posts Strong Phase 3 HAE Prophylaxis Data for Oral Deucrictibant XR - TipRanks
Pharvaris stock surges 27% on positive trial data By Investing.com - Investing.com South Africa
Pharvaris stock surges 27% on positive trial data - Investing.com
Pharvaris reports positive phase 3 results for HAE drug - Investing.com
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks - Yahoo Finance UK
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It - marketbeat.com
CureVac NV (CVAC) Peer Comparison – Compare with Others - Value Research
Pharvaris (PHVS) Pulls Back 4.5% to $35.32 as Shares Approach Key SupportFibonacci Time Zone - vinanet.vn
Pharvaris (NASDAQ:PHVS) Hits New 12-Month HighWhat's Next? - MarketBeat
Foresite Capital Management V, LLC's Pharvaris NV(PHVS) Holding History - GuruFocus
Pharvaris CEO Berndt Modig Sells 2,292 Shares Under Rule 10b5-1 Trading Plan - Kalkine Media
Insider Selling: Pharvaris (NASDAQ:PHVS) CEO Sells 2,292 Shares - MarketBeat
Pharvaris (PHVS) CEO sells 2,292 shares after RSU vesting - Stock Titan
What is HC Wainwright's Forecast for Pharvaris Q3 Earnings? - MarketBeat
Pharvaris NV (PHVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Research Analysts Issue Forecasts for Pharvaris Q4 Earnings - MarketBeat
General Atlantic group (PHVS) discloses 5.36M Pharvaris shares, 7.6% ownership - Stock Titan
PHVS (NASDAQ: PHVS) holder Berndt Modig plans 2,292-share stock sale - Stock Titan
H.C. Wainwright reiterates Pharvaris stock rating on regulatory progress By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Pharvaris stock rating on regulatory progress - Investing.com
Pharvaris President Lu Peng Reports Two RSU Tax Withholding Share Dispositions - Kalkine Media
PHVS Maintains Outperform Rating -- Price Target Raised to $52.0 - GuruFocus
Pharvaris Could See Significant Upside on Positive Phase 3 Data, RBC Says - marketscreener.com
PHVS Maintains Rating by Citizens -- Price Target Raised to $75. - GuruFocus
RBC Adjusts PT on Pharvaris to $52 From $51, Maintains Outperform Speculative Risk Rating - marketscreener.com
Citizens raises Pharvaris stock price target to $75 on trial progress - Investing.com Australia
Pharvaris (NASDAQ:PHVS) Reaches New 12-Month HighWhat's Next? - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Pharvaris Q2 EPS of $(0.81) misses $(0.74) analyst estimate - scanx.trade
Pharvaris N.V. reports results for the quarter ended June 30Earnings Summary - TradingView
(PHVS) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Finanzdaten der Pharvaris Nv-Aktie (PHVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pharvaris Nv-Aktie (PHVS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Modig Berndt | Chief Executive Officer |
Aug 14 '26 |
Sale |
34.77 |
2,292 |
79,686 |
130,625 |
0.29%
4.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):